Obesity-Related Tissue Damage
|
|
- Clement Wells
- 5 years ago
- Views:
Transcription
1 Obesity-Related Tissue Damage Anna Mae Diehl, MD Duke University Sept 2018 No conflicts to disclose
2 Obesity-Related Tissue Damage Impacts virtually every organ Cardiovascular System (ASCVD, CHF) Endocrine (Type 2 DM) Kidneys (CRF) Brain (CVA, Dementia) GI Tract (BE, Cancers, NAFLD) Strongly correlates w/ Metabolic Syndrome (MetS) Dyslipidemia/Insulin-resistance/Hypertension Targets non-healthy subset of obese individuals Hepatic steatosis differentiates non-healthy from healthy obese Samocha-Bonet D, Obes Rev 2014 Why? (There s more to it than fat)
3 Obesity-related comorbidity* Associates with T2DM, MetS Extremely prevalent NonAlcoholic Fatty Liver Disease Afflicts at least 25% American adults Incidence rising Epidemic of childhood/adolescent obesity * Can occur without obesity (e.g., lipodystrophy)
4 NAFLD Two Main Subtypes US Adult Population (100%) NonAlcoholic Fatty Liver (a.k.a. simple steatosis ) NAFLD (~25%) NAFL (75%) NASH (25%) NonAlcoholic SteatoHepatitis (a.k.a. NASH )
5 NAFLD Pathologic Spectrum with Differential Prognosis NAFL NASH Dynamic! Hepatocyte Fat Hepatocyte Death Cirrhosis PLC
6 Outcome of Injury Dictated by Efficacy of Repair Dying Cells Signals Replacements Dead Cells Replacements Recovery Death Disease Acute Liver Failure Cirrhosis
7 NAFLD Fibrosis Severity Independent predictor for Liver-specific morbidity Ascites, varices, encephalopathy F0-1 (1) < F-2 (7.5x) < F-3 (13.8x) < F-4(47.5x) Liver-specific mortality/olt 7x increased in F-4 versus F-0 All-cause mortality 3x increased in F3-4 versus F-0 NOT predicted by NAFLD Activity Score (NAS), NAS components (steatosis, inflammation, ballooning) Ekstedt M, et al. Hepatology 2014 Angulo P, et al. Gastroenterology Gastroenterology 2015
8 Sensitivity Liver Gene Expression Differences in Mild (F0-1) vs. Severe (F3-4) NAFLD Heirarchical Clustering ROC curve (Mild vs. Severe NAFLD) Top 100 probes with 1000 training/testing splits N=40 N=32 1 0,8 0,6 0,4 0, , Specificity 64 gene signature differentiates Severe from Mild NAFLD Logistic Regression Analysis 20 genes Independently correlate with NAFLD severity Moylan, C. et al. Hepatology Feb, 2014.
9 Functional Analysis of Severe NAFLD Transcriptome Onco-fetal Reprogramming In Diseased Liver? Fetal-like Top Biological Functions Diseases and Disorders p value Genes (n) Cancer Reproductive System Disease Gastrointestinal Disease Cardiovascular Disease Genetic Disorder Molecular and Cellular Functions Cellular Movement Cellular Growth and Proliferation Cell Morphology Cellular Assembly and Organization Top Ingenuity Pathways Tissue remodeling Regeneration Wound healing Progenitor Cells Development Moylan, C. et al. Hepatology Feb, Protein Synthesis Top Canonical Pathways Ratio Fatty Acid Metabolism /184 Valine, Leucine and Isoleucine Degradation /107 Bile Acid Biosynthesis /105 Glycine, Serine and Threonine Metabolism /147 Butanoate Metabolism /128 Top Toxicology Functions Hepatotoxicity qrt-pcr Validation Hepatocellular Carcinoma Liver Cholestasis Liver Necrosis/Cell Death Liver Hepatitis Liver Proliferation
10 Cirrhotic Liver Pro-carcinogenic Cancer risk increases with duration of exposure Greater than 2% per year in cirrhosis Second primaries are the norm Field effect Fibrosis Marker of Defective Repair NAFLD-induced Cirrhosis Activated endothelia, immune cells, progenitors, myofibroblasts, fibrous matrix
11 Adult Hypothesis Transient Liver injury Regenerate Onco-fetal Reprogramming Persistent Adult Fetal Healthy Fetal Diseased ALF Cirrhosis Cancer
12 Implications for NASH? Pathways that regulate cell plasticity to accomplish organogenesis during development reactivate to regenerate the liver during NASH Dysregulation of these pathways promotes outgrowth of cell types that are necessary, but not sufficient, for effective regeneration/recovery Myofibroblasts, hepatocyte progenitors Persistent accumulation of these repair-related cell types impedes effective repair + promotes development of cirrhosis [and liver cancer]
13 Hedgehog Pathway Regulates fate decisions in stem/progenitor cells Oncofetal pathway Active in development Down-regulated at birth Re-activates in many adult cancers Activated in multiple liver diseases before cancer develops Promotes myofibroblast accumulation Drives fibrosis progression in NASH animal models Promotes outgrowth of immature hepatocytes Adenomas in obese women with NAFLD characterized by chromosomal translocation that activates HH signaling Machado & Diehl, J Hepatol, Oct 2017 Nault, Gastroenterology 2017
14 NASH Lipotoxity ER Stress Ubiquitinated cytoskeletal proteins accumulate Stop making Cytoskeletal proteins K8/18 (brown)/ub (red) pretreatment VitE responder (patient X ) (400x) Hepatocytes swell (balloon) Damaged hepatocytes generate DAMS (Shh) Rangwala F, et al. J Pathol 2011 Guy CD, et al. Hepatology 2015 Shh (brown) pretreatment VitE responder (patient X ) (400x)
15 Ballooned hepatocytes surrounded by Hh-responsive myofibroblasts Guy CD, et al. Hepatology; Jan 2015 IHC: gli-2 (red, Hh-responsive) α-sma (brown, myofibroblast)
16 Reducing hepatocyte lipotoxicity (ballooning) reduces hepatic production of Hedgehog ligands Vit E Shh (brown) pre-treatment VitE responder (patient X ) (400x) Shh post-treatment VitE responder (patient X ) (400x) Guy CD, et al. Hepatology; Jan 2015
17 Reducing Hedgehog ligands reduces accumulation of Hh-responsive myofibroblasts Vit E Pre-treatment VitE responder (patient X ) (400x) Post-treatment VitE responder (patient X ) (400x) Guy CD, et al. Hepatology; Jan 2015 IHC: gli-2 (red, Hh-responsive) α-sma (brown, myofibroblasts)
18 Hepatocyte derived Hh ligands drive fibrosis in NASH Wang X, et al. Cell Metab 2016
19 Autocrine-Paracrine Hedgehog Signaling Orchestrates Wound Healing Response SIGNALS Promote outgrowth of liver progenitors Stimulate vascular remodeling Recruit immune cells Regulate immune cell polarization Regulate matrix remodeling Control size of MF populations
20 Wound Healing Response Double Edged Sword SIGNALS Promote outgrowth of liver progenitors CANCER Stimulate vascular remodeling PORTAL HTN Recruit immune cells Regulate immune cell polarization INFLAMMATION Regulate matrix remodeling Control size of MF populations FIBROSIS
21 Hedgehog Interacts with Other Onco-Fetal Pathways Shh promotes activation of Yap1 (Hippo kinase target) in neural progenitors Hedgehog signaling promotes Yap1 activation in hepatic stellate cells Yap1 activity is necessary to stellate cells to be myofibroblastic
22 mrna Fold Change mrna Fold Change mrna Fold Change Hedgehog MF-HSC Q-HSC Smo Gli1 asma Collagen 1a1 PPARg * LRAT * * * * * Yap mrna Yap target genes Yap activity YAP CTGF AREG AdGFP AdCre * * * pyap S127 YAP plats1 T1079 Lats1 β-actin 1,5 1 0,5 0 YAP Lamin B NT * * * * c NT YAPΔ1 YAPΔ2 * Yap MF-HSC Hh signaling Swiderska-Syn et al. Hepatology 2017
23 Hippo Kinase Pathway Regulates fate decisions in stem/progenitor cells Hippo kinases INactivate pluripotent transcription co-factors (YAP1, TAZ) Phospho-YAP1 degraded, not retained in nucleus target genes off LOSS of YAP1 formation of epithelia Oncofetal regulation INactive in development UP-regulated at birth SILENCED in many adult cancers Silenced during adult liver regeneration (YAP1/TAZ accumulate) YAP1 (ductal cells)/taz (hepatocytes) MF accumulation NASH fibrosis
24 YAP Accumulation of Hh-responsive MF and Immature Ductal Cells Correlate with Fibrosis Stage in Human NAFLD Not-NASH Fibrosing NASH 2 P= ,5 Shh 1 0,5 0 F0-F1 F2-F4 asma (MF) R=0.642 P<0.001 R=0.562 P<0.001 K19 Yap1 YAP = brown K19 = green Immature Ductal Cells Machado et al. J Hepatol 2015
25 Fibrosis Severity Parallels YAP1 Accumulation in Ductular Cells In Mouse Models of NASH Machado MV, et al. J Hepatol; Oct 2015
26 Summary #1 Pathways that are high in fetal livers/low in healthy adult livers are reactivated in NASH Hedgehog ON Activate downstream targets (Smo/Glis) fibrosis, progenitors Pathways that are low in fetal liver/high in healthy adult livers are silenced in NASH Hippo kinases OFF Activate Yap/Taz fibrosis, progenitors Fetal Reprogramming occurs in NASH
27 Clinical Implications What signals push HSC to become fibrogenic myofibroblasts? Hedgehog, Yap (Notch, Wnt, Leptin, Others??) Can HSC resist or recover from myofibroblastic (MF) reprogramming? Yes? (recover) Is there inter-individual variability in HSC susceptibility to MF programming? Impact of environmental exposures (diet, microbiome), age, genetic/epigenetic forces? Basis for heterogeneous NAFLD outcomes?? Metabolic syndrome??
28 Hypothesis Liver injury Regenerate Hh OFF Adult Fetal Healthy Transient Onco-fetal Reprogramming Hh ON Persistent Hh OFF Adult Fetal Diseased NASH Cirrhosis Cancer Hh ON
29 Hypothesis Liver injury Regenerate Hh OFF Adult Fetal Healthy Transient Insufficient Onco-fetal Reprogramming Hh ON Hh OFF Adult Fetal Hh ON Diseased Degeneration Atrophy
30 Hedgehog Controls White adipose development Vasculogenesis/angiogenesis Pancreatic islet cell mass Regulates and is regulated by lipids Ligands: lipid-modified, carried in lipoproteins Signaling activity directly regulated by sterols Modulates lipid/glucose metabolism Inhibits lipogenesis Promotes FA b-oxidation Promotes glycolysis Inhibits gluconeogenesis Liver correlate of the MetS NAFLD Pospisilik & Esterhauser, Cell 2012 & 2014; Eaton, Development 2009 & PLoS Biology 2013; Diehl, Gastroenterology 2014; Matz-Soja, Elife 2017; Myers, PNAS 2017; Huang Cell, 2018
31 Changes in Hedgehog activity linked to Obesity-Metabolic Syndrome in Humans Mutation in Hedgehog inhibitor (DYRK1B) visceral adiposity, T2DM, premature CAD in 3 kindreds Mutation potentiates DRYK1B Hedgehog inhibitory activity Hedgehog inhibition known to cause adiposity (flies and mice) reduced viability of pancreatic beta cells (mice) decreased angiogensis (mice) Keramati et al. New Engl J Med 2014; 370:
32 Hedgehog Suppression Promotes Hepatic Steatosis Humans with Smo mutations that inhibit Hedgehog signaling hepatic steatosis Mice with impaired Hedgehog signaling (haploinsufficiency of Gli2) obesity, fatty liver but protected from diet-induced NASH/fibrosis Guillen-Sacoto, J Hepatol 2017
33 Summary #2 Inability to reactivate pathways that are high in fetal livers/low in healthy adult livers promotes obesity, MetS, fatty liver (NAFL) Hedgehog OFF Can t activate downstream targets (Smo/Glis) degenerative diseases? Depletion of stem/progenitor cell populations?? Defective Fetal Reprogramming in NAFLD
34 Hypothesis Tissue injury Regenerate Adult Transient Onco-fetal Reprogramming Excessive Fetal Healthy Insufficient Adult Adult Fetal Fetal Fatty liver Degeneration Atrophy Diseased NASH Cirrhosis Cancer
35 Obesity-Related Tissue Damage Summary Characterized by dysregulation of pathways that control fetal-adult switching Both over- and under-activation of the fetal program tissue damage Over-activation may promote fibrosis, cancer Under-activation/pre-mature termination may deplete stem cell pools and promote degenerative diseases More research is needed to delineate factors that regulate fetal-adult/adult-fetal programming Genetic Epigenetic Environmental
36 Diehl Lab Jason Sicklick* Steve Choi Alessia Omenetti* Youngmi Jung* Raf Witek* Greg Michelotti* Vanessa Teaberry* Fatima Rangwala* George Philips* Isaac Chan* Guanhua Xie* Yuping Chen* Gamze Karaca* Marzena Swiderska-Syn* Wing Kin Syn* Mariana Machado* Jeongeun Hyun She Hoon Oh Richard Premont Mark Jewell George Dalton Kuo Dui * Former lab members Thanks! Duke Collaborators Cindy Guy Jack Keene Matt Friedersdorf Outside Collaborators Undayan Apte (Yap flox mice) Funding Sources NIAAA/NIDDK Duke Endowment
NASH Bench to Bedside
NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent
More informationRepair-associated inflammation in nonalcoholic fatty liver disease
LINACRE LECTURE Clinical Medicine 2013, Vol 13, No 6: s15 s19 Repair-associated inflammation in nonalcoholic fatty liver disease Wing-Kin Syn ABSTRACT The mechanisms that drive non-alcoholic fatty liver
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood
More informationWith the rise in obesity, nonalcoholic fatty. Hedgehog Pathway and Pediatric Nonalcoholic Fatty Liver Disease
Hedgehog Pathway and Pediatric Nonalcoholic Fatty Liver Disease Marzena Swiderska-Syn, 1 Ayako Suzuki, 1 Cynthia D. Guy, 2 Jeffrey B. Schwimmer, 3 Manal F. Abdelmalek, 1 Joel E. Lavine, 4 and Anna Mae
More informationFOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB
BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-18-095 Title: Insulin Receptor Substrate 2:A Bridge between Hippo and AKT Pathways Article Type: Perspective (Invited Only) Keywords:
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationNew insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College
New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationHepaRG LX2. HepaRG HepaRG LX2 LX2
C Supporting Figure 1. Experimental design of s between and cells. (A) -hepatocytes were isolated from a 30 days of -progenitors. Differentiation into mature hepatocytes was achieved following a 2-weeks
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationNKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease
< Additional materials are published online only. To view these files please visit the journal online (http://dx.doi.org/ 10.1136/gutjnl-2011-301857). 1 Division of Gastroenterology, Department of Medicine,
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More information(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes
(A) (B) (C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes representing the minimal histological criteria of steatohepatitis)
More informationClinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationHow Will New Therapies Affect HCC Development?
How Will New Therapies Affect HCC Development? July 6, 2018 Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of Medicine
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationNonalcoholic steatohepatitis (NASH) is a
Osteopontin is Induced by Hedgehog Pathway Activation and Promotes Fibrosis Progression in Nonalcoholic Steatohepatitis Wing-Kin Syn, 1,2 Steve S. Choi, 1,3 Evaggelia Liaskou, 2 Gamze F. Karaca, 1 Kolade
More informationQuantitative Imaging Goals for NIDDK
Quantitative Imaging Goals for NIDDK Maren R. Laughlin Senior Advisor Quantitative Imaging Goals for NIDDK Monitor progression and response to therapy of disease in liver kidney and urological organs bone
More informationHepatocellular Adenomas: Genetics & Imaging Update 2017
No financial disclosures Hepatocellular Adenomas: Genetics & Imaging Update 2017 Srinivasa Prasad MD The UT MD Anderson Cancer Center Aims & Objectives To provide a current update on genetics & molecular
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationUniversity of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba
University of Groningen Non-alcoholic fatty liver disease Sheedfar, Fareeba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationSteatotic liver disease
Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationWHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi
More informationAn Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationPrimary biliary cirrhosis (PBC) is a chronic cholestatic
RAPID COMMUNICATION Bile Ductules and Stromal Cells Express Hedgehog Ligands and/or Hedgehog Target Genes in Primary Biliary Cirrhosis Youngmi Jung, 1 Shannon J. McCall, 2 Yin-Xiong Li, 1 and Anna Mae
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationFatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London
Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationAdvances in Understanding Hepatic Fibrosis and Chronic Liver Disease
Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationMetabolic Syndrome and HCC. Jacob George
Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For
More informationYun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019
Combination Therapy of Seladelpar and Liraglutide Attenuates Obesity, Hepatic Steatosis and Fibrosis in a Diet-induced and Biopsy-confirmed Mouse Model of NASH Yun-Jung Choi, Jiangao Song, Jeff D. Johnson,
More informationAlcoholic hepatitis is a drug-induced disorder
Alcoholic hepatitis is a drug-induced disorder Gyongyi Szabo, MD, PhD Professor of Medicine University of Massachusetts Medical School Source: 2 Sobernation.com Clinical Progression of ALD Mortality Acute
More informationUnderstanding Root Cause: Pathogenesis of Hepatic Fibrosis
10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis
More informationNatural history of α-1-atd in children
Natural history of α-1-atd in children Agnieszka Bakuła Dpt of Gastroenterology, Hepatology, Nutrition Disorders and Paediatrics The Children s Memorial Health Institute Warsaw, Poland Topics to be discussed
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationLipid and Bile Acids as NAFLD- Related Biomarkers
Lipid and Bile Acids as NAFLD- Related Biomarkers Puneet Puri, MBBS, MD Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University, Richmond, VA 1st International Workshop
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationOctober 2009 EPITHELIAL-MESENCHYMAL TRANSITION AND NAFLD mon types of chronic liver disease in humans,5 and there is already strong evidence that incr
GASTROENTEROLOGY 2009;137:1478 1488 Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease WING KIN SYN,* YOUNGMI JUNG,* ALESSIA OMENETTI,* MANAL
More informationThe Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego
The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease Ekihiro Seki, M.D.,Ph.D. University of California San Diego - A manufactured chemical. - Does not exist naturally. Carbon tetrachloride
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationNegative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α
Negative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α Mahnaz Janghorban, PhD Dr. Rosalie Sears lab 2/8/2015 Zanjan University Content 1. Background (keywords: c-myc, PP2A,
More informationHepatitis C wi w t i h Ju J dy y W y W a y t a t t
Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis
More informationNottingham Patterns of liver fibrosis and their clinical significance
Nottingham 2006 Patterns of liver fibrosis and their clinical significance Alastair D Burt Professor of Pathology and Dean of Clinical Medicine University of Newcastle upon Tyne Collapse of reticulin
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationLinda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes
More informationAntifibrotic therapy: between hopes and reality. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy
Antifibrotic therapy: between hopes and reality Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy Disclosures Abbvie: consultant fees AstraZeneca: consultant fees
More informationLiver Disease NASH/Fibrosis Model
Liver Disease NASH/Fibrosis Model Please contact: Dipti Deshpande PhD ddeshpande@woodlandpharma.com or Carol Gebert PhD cgebert@woodlandbiosciences.com 617-513-5280 Liver Diseases Comprise a Growing Market
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationIL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA
UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationExploring a Link Between Spy1 and Hepatocellular Carcinoma Progression
University of Windsor Scholarship at UWindsor UWill Discover Undergraduate Conference UWill Discover 2016 Mar 29th, 4:00 PM - 5:00 PM Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression
More informationFollow-up of pediatric chronic liver disease
IV CONVEGNO ITALO-BRASILIANO DI PEDIATRIA E NEONATOLOGIA SALVADOR DE BAHIA 21-23 MARZO 2006 Follow-up of pediatric chronic liver disease Antonio Colecchia, Luca Laudizi Dpt of Internal Medicine and Gastroenterology
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationPathogenesis of Diabetes Mellitus
Pathogenesis of Diabetes Mellitus Young-Bum Kim, Ph.D. Associate Professor of Medicine Harvard Medical School Definition of Diabetes Mellitus a group of metabolic diseases characterized by hyperglycemia
More informationDisclosures. Outline. Extracellular Vesicles in Fatty Liver Disease. From Contributors to disease pathogenesis to novel biomarkers
Extracellular Vesicles in Fatty Liver Disease From Contributors to disease pathogenesis to novel biomarkers Ariel Feldstein, M.D. Professor of Pediatrics Chief, Division of Pediatric Gastroenterology Hepatology
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationNonalcoholic fatty liver disease (NAFLD) is
STEATOHEPATITIS/METABOLIC LIVER DISEASE Hedgehog Pathway Activation Parallels Histologic Severity of Injury and Fibrosis in Human Nonalcoholic Fatty Liver Disease Cynthia D. Guy, 1 Ayako Suzuki, 2 Marzena
More informationNonalcoholic fatty liver disease (NAFLD) is the most common
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1249 1254 Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients DIMA L. DIAB,* LISA YERIAN,
More informationFuture of stem cell therapy in liver disease Domenico ALVARO, MD Sapienza, University of Rome, Italy
Future of stem cell therapy in liver disease Domenico ALVARO, MD Sapienza, University of Rome, Italy AISF, 17 th Pre Meeting Future Scenarios in Hepatology, 18-02-2015. CELL THERAPY and LIVER DISEASES
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationResearch in Hepatology What is hot and what is not!
Research in Hepatology What is hot and what is not! Anna SF Lok, MD University of Michigan Ann Arbor, MI, USA Please consider the environment before printing this PowerPoint Outline How to define hot?
More informationParis Hepatology Conference PROGNOSIS OF NASH
Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research
More informationMetabolic Changes Associated with Stress. Larry H. Bernstein Yale University
Metabolic Changes Associated with Stress Larry H. Bernstein Yale University Starvation vs Cachexia Starvation - reversed by feeding Cachexia - metabolically driven Body weight inaccurate - failure to distinguish
More informationMetabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
More informationTherapeutic targets and the management of NASH
Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationDefining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
More informationHealing & Repair. Tissue Regeneration
Healing & Repair Dr. Srikumar Chakravarthi Repair & Healing: Are they same? Repair :Regeneration of injured cells by cells of same type, as with regeneration of skin/oral mucosa (requires basement membrane)
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationGR-MD-02 for Indication of NASH Cirrhosis: NASH-CX Clinical Trial Results
GR-MD-02 for Indication of NASH Cirrhosis: NASH-C Clinical Trial Results Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 1 2018 2017 Galectin
More informationWeek 3 The Pancreas: Pancreatic ph buffering:
Week 3 The Pancreas: A gland with both endocrine (secretion of substances into the bloodstream) & exocrine (secretion of substances to the outside of the body or another surface within the body) functions
More informationCholesterol and Sphingolipids in Non-Alcoholic fatty liver disease.
Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease. José C. Fernández-Checa Liver Unit, Hospital Clinic CIBEK and IDIBAPS Instituto Investigaciones Biomédicas Barcelona Consejo Superior
More informationConflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationMicroRNA dysregulation in cancer. Systems Plant Microbiology Hyun-Hee Lee
MicroRNA dysregulation in cancer Systems Plant Microbiology Hyun-Hee Lee Contents 1 What is MicroRNA? 2 mirna dysregulation in cancer 3 Summary What is MicroRNA? What is MicroRNA? MicroRNAs (mirnas) -
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationPitfalls in the diagnosis of well-differentiated hepatocellular lesions
2013 Colorado Society of Pathology Pitfalls in the diagnosis of well-differentiated hepatocellular lesions Sanjay Kakar, MD University of California, San Francisco Outline Hepatocellular adenoma: new WHO
More information